A population pharmacokinetic model for early follow-up dosing of tacrolimus in Tunisian kidney transplant recipients
In the first 3 months post-transplant, tacrolimus CL/F was significantly influenced by <i>CYP3A5</i> genotype, BMI, hematocrit, and time after transplantation. The model supports individualized dose adjustment; prospective external validation and a simple dose-adjustment algorithm are warranted to facilitate clinical implementation.
Authors
- Dennis A. Hesselink (ORCID: https://orcid.org/0000-0003-1871-1962)
- Dorra Amor
- Marith I. Francke (ORCID: https://orcid.org/0000-0001-5641-8375)
- Ali Bouslama
- Amani Abderahmene
- Brenda C. M. de Winter (ORCID: https://orcid.org/0000-0002-4452-8443)
- W. Sahtout
- Asma omezzine
- Louise M. Andrews (ORCID: https://orcid.org/0000-0001-8271-3685)
- Meriam Ammar
- Dorsaf Zellama
- Azzabi Awatif
Institutions
- Erasmus MC (NL)
- Hôpital Sahloul (TN)
- Erasmus MC Cancer Institute (NL)
- Meander Medisch Centrum (NL)
Publication Details
- Journal
- Personalized Medicine
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/17410541.2025.2606641
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00